Article
Hematology
Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi
Summary: High-dose melphalan improves progression-free survival in multiple myeloma, but it causes more mutations in surviving myeloma cells at relapse. These newly acquired mutations are associated with DNA damage and double-stranded breaks, and are predominantly found on the transcribed strand. A machine learning model based on this unique pattern can predict patients who will receive high-dose melphalan with high accuracy.
Article
Hematology
Murielle Roussel, Valerie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chretien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valere Malfuson, Arnaud Jaccard, Pascal Lenain, Cecile Borel, Benjamin Hebraud, Omar Benbrahim, Veronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Veronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Helene Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurene Colin, Pascale Olivier, Soraya Wuilleme, Herve Avet-Loiseau, Jill Corre, Michel Attal
Summary: This study found that the combination of bortezomib and high-dose melphalan did not improve outcomes or efficacy endpoints in patients with multiple myeloma compared to high-dose melphalan alone.
Article
Oncology
Naresh Bumma, Binod Dhakal, Raphael Fraser, Noel Estrada-Merly, Kenneth Anderson, Cesar O. Freytes, Gerhard C. Hildebrandt, Leona Holmberg, Maxwell M. Krem, Cindy Lee, Lazaros Lekakis, Hillard M. Lazarus, Hira Mian, Hemant S. Murthy, Sunita Nathan, Taiga Nishihori, Ricardo Parrondo, Sagar S. Patel, Melhem Solh, Christopher Strouse, David H. Vesole, Shaji Kumar, Muzaffar H. Qazilbash, Nina Shah, Anita D'Souza, Surbhi Sidana
Summary: This study found that bortezomib monotherapy or combination therapy did not show superior outcomes compared to lenalidomide alone as maintenance treatment in patients with high-risk multiple myeloma. Therefore, until prospective data from randomized clinical trials are available, post-transplant therapy should be individualized and consideration should be given to enrolling patients in clinical trials targeting novel therapeutic strategies for high-risk multiple myeloma. Lenalidomide should continue to be a cornerstone of treatment.
Article
Hematology
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie L. Fonder, Morie A. Gertz, Wilson Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Summary: This study examined the incidence of thromboembolism in newly diagnosed multiple myeloma patients receiving lenalidomide-based regimens and found that the risk was highest with the KRd regimen, with significantly lower survival rates among patients who developed thromboembolism.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Hiroyuki Muranushi, Junya Kanda, Masayuki Kobayashi, Takeshi Maeda, Toshiyuki Kitano, Masaaki Tsuji, Yasunori Ueda, Takayuki Ishikawa, Masaharu Nohgawa, Mitsumasa Watanabe, Kazunori Imada, Toshinori Moriguchi, Mitsuru Itoh, Hitoshi Ohno, Akihito Yonezawa, Hirokazu Hirata, Nobuyoshi Arima, Kohsuke Asagoe, Naoyuki Anzai, Kayoko Nagata, Shinji Yasuno, Yoshihiro Kuwabara, Hiromi Kitao, Ihhwa Kim, Kiyomi Kawagishi, Kenji Ueshima, Shinjiro Tominari, Takeo Nakayama, Kouhei Yamashita, Akifumi Takaori-Kondo
Summary: The study aimed to evaluate the efficacy and safety of VCD induction/consolidation and bortezomib maintenance in Japanese patients with NDMM. The overall response rate after induction therapy was 71%, with CR/sCR and VGPR rates of 26% and 17% after ASCT. The 2-year overall survival and progression-free survival rates were 92.5% and 62.6% respectively. VCD induction/consolidation and bortezomib maintenance showed high CR/sCR rate and good survival in Japanese NDMM patients.
Article
Biophysics
Charalampos Charalampous, Utkarsh Goel, Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, David Dingli, Francis Buadi, Prashant Kapoor, Taxiarchis Kourelis, Rahma Warsame, William J. Hogan, Shaji Kumar
Summary: This study examined the impact of the time interval between the end of induction therapy and autologous hematopoietic transplantation on the survival of multiple myeloma patients. The results showed that a shorter interval was associated with a longer progression-free survival, particularly for patients with a partial response during induction.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biochemistry & Molecular Biology
Sang Wu Lee, Soo-Keun Yeon, Go Woon Kim, Dong Hoon Lee, Yu Hyun Jeon, Jung Yoo, So Yeon Kim, So Hee Kwon
Summary: The HDAC6-selective inhibitor A452 has been shown to overcome bortezomib resistance in multiple myeloma by decreasing the activation of resistant markers and synergistically inhibiting cancer cell growth when used in combination with other drugs. This discovery highlights the potential of A452 as a promising therapy for bortezomib-chemoresistant multiple myeloma patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Elias K. Mai, Kaya Miah, Uta Bertsch, Jan Duerig, Christof Scheid, Katja C. Weisel, Christina Kunz, Markus Munder, Hans-Walter Lindemann, Maximilian Merz, Dirk Hose, Anna Jauch, Anja Seckinger, Steffen Luntz, Sandra Sauer, Stephan Fuhrmann, Peter Brossart, Ahmet Elmaagacli, Martin Goerner, Helga Bernhard, Martin Hoffmann, Marc S. Raab, Igor W. Blau, Mathias Haenel, Axel Benner, Hans J. Salwender, Hartmut Goldschmidt
Summary: Intensive upfront therapy for newly-diagnosed multiple myeloma patients up to age 70 is feasible, with similar treatment adherence across age groups but increased overall toxicity in older patients. Age does not impact progression-free or overall survival outcomes in this setting.
Article
Biophysics
Vanille Laurent, Clementine Fronteau, Chloe Antier, Pascale Dupuis, Benoit Tessoulin, Thomas Gastinne, Beatrice Mahe, Nicolas Blin, Viviane Dubruille, Anne Lok, Patrice Chevallier, Thierry Guillaume, Alice Garnier, Pierre Peterlin, Amandine Le Bourgeois, Sophie Vantyghem, Mourad Tiab, Pascal Godmer, Sophie Sadot, Marion Loirat, Adrien Trebouet, Nicolas Cormier, Steven Le Gouill, Philippe Moreau, Cyrille Touzeau
Summary: The triplet-drug regimens VTD and VRD are standard of care induction prior to ASCT in myeloma. VRD induction was associated with more frequent use of plerixafor, increased number of apheresis, and higher collection failure rate compared to VTD. The median number of CD34-positive cells was lower in the VRD group, although the majority of patients in both groups underwent ASCT. Optimizing stem-cell collection strategy is crucial, especially in the context of tandem transplantation and incorporating anti-CD38 monoclonal antibody into induction.
BONE MARROW TRANSPLANTATION
(2021)
Article
Multidisciplinary Sciences
Mengmeng Dong, Jinna Zhang, Xiaoyan Han, Jingsong He, Gaofeng Zheng, Zhen Cai
Summary: This study retrospectively analyzed clinical data of 155 MM patients and found that baseline PN was age-related, leading to more severe BiPN during bortezomib induction therapy and worse PN outcome after induction therapy. MM patients with baseline PN also had worse PFS and OS.
SCIENTIFIC REPORTS
(2022)
Review
Hematology
Georgia J. McCaughan, Sara Gandolfi, John J. Moore, Paul G. Richardson
Summary: For patients with newly diagnosed multiple myeloma, optimizing induction therapy is crucial for long-term disease control. The current standard of care involves the combination of lenalidomide and bortezomib with dexamethasone (RVD) as induction treatment, followed by maintenance until disease progression.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos
Summary: Multiple myeloma is an incurable disease, and patients require long-term treatment. Despite the introduction of new therapies, drug resistance remains the most critical factor in choosing the appropriate treatment. Currently, three-drug regimens are the standard approach for managing relapsed disease.
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Shaji K. Kumar
Summary: Treatment with 4-drug regimens is recommended for newly diagnosed multiple myeloma (MM) patients, and daratumumab + lenalidomide and dexamethasone is the standard treatment. Lenalidomide is the standard maintenance therapy, but more intensive regimens can be considered in some cases. Up-front autologous stem cell transplantation (ASCT) is more effective, but delaying transplantation until disease progression is acceptable. CAR T-cell therapy and bispecific T-cell engagers have shown durable responses in MM patients.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Medicine, General & Internal
Shirlene Sim, Hang Quach, Tina Pham, Veronica Smooker, Robin Filshie
Summary: This study retrospectively analyzed the PBSC mobilization outcomes of 56 multiple myeloma patients and compared different induction strategies. The results showed that patients mobilized with G-CSF plus cyclophosphamide achieved higher CD34 cell counts, allowing for sufficient cells for autologous stem cell transplantation in the majority of patients. Therefore, the upfront use of a cyclophosphamide-based mobilization strategy after VRd induction can increase the success rate.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Oncology
Massimo Gentile, Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Anna Grazia Recchia, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Vincenzo Fraticelli, Ernesto Vigna, Cirino Botta, Giovanni Tripepi, Graziella D'Arrigo, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Gian Matteo Rigolin, Davide Rossi, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Antonio Cuneo, Robin Foa, Valter Gattei
Article
Hematology
Antonio Cuneo, Lydia Scarfo, Gianluigi Reda, Marzia Varettoni, Francesca Maria Quaglia, Monia Marchetti, Lorenzo De Paoli, Francesca Re, Daniela Pietrasanta, Gian Matteo Rigolin, Lorella Orsucci, Adalberto Ibatici, Valter Gattei, Francesca R. Mauro, Livio Trentin, Luca Laurenti, Roberto Marasca, Robin Foa
Article
Hematology
Andrea Corbingi, Idanna Innocenti, Annamaria Tomasso, Raffaella Pasquale, Andrea Visentin, Marzia Varettoni, Elena Flospergher, Francesco Autore, Francesca Morelli, Livio Trentin, Gianluigi Reda, Dimitar G. Efremov, Luca Laurenti
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Surgery
Irene Cassaniti, Anna A. Colombo, Paolo Bernasconi, Michele Malagola, Domenico Russo, Anna P. Iori, Corrado Girmenia, Raffaella Greco, Jacopo Peccatori, Fabio Ciceri, Francesca Bonifazi, Elena Percivalle, Giulia Campanini, Giulia Piccirilli, Tiziana Lazzarotto, Fausto Baldanti
Summary: This study highlights the importance of considering the clinical relevance of HCMV DNAemia during LMV prophylaxis in allo-HSCTRs.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Letter
Hematology
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Ernesto Vigna, Enrica Antonia Martino, Francesco Mendicino, Cirino Botta, Daniele Caracciolo, Ramona Cassin, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foa, Manlio Ferrarini, Valter Gattei, Massimo Gentile
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Letter
Oncology
Arturo Bonometti, Emanuela Boveri, Marzia Varettoni, Andrea Ripamonti, Sara Fraticelli, Marco Lucioni, Silvia Zibellini, Chiara Elena, Daniela Pietra, Luca Arcaini, Marco Paulli
LEUKEMIA & LYMPHOMA
(2021)
Letter
Hematology
Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Anna Grazia Recchia, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Enrica Antonia Martino, Ernesto Vigna, Giovanni Tripepi, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Ozren Jaksic, Jacopo Olivieri, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foa, Manlio Ferrarini, Valter Gattei, Massimo Gentile
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Letter
Hematology
Irene Defrancesco, Marcella Visentini, Silvia Zibellini, Ylenia Aura Minafo, Sara Rattotti, Virginia Valeria Ferretti, Ettore Rizzo, Marzia Varettoni, Marco Frigeni, Alessandro Pulsoni, Milvia Casato, Stefania Colantuono, Marianna Rossi, Chiara Candido, Caterina Zerbi, Fabio Bergamini, Caterina Cristinelli, Nicole Fabbri, Michele Merli, Valentina Zuccaro, Raffaele Bruno, Marco Paulli, Luca Arcaini
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Letter
Hematology
Marzia Varettoni, Ester Orlandi, Silvia Zibellini, Marianna Rossi, Massimo Gentile, Elena Flospergher, Virginia V. Ferretti, Ettore Rizzo, Matteo G. Della Porta, Sara Rattotti, Chiara Cavalloni, Fabio Bergamini, Caterina Cristinelli, Nicole Fabbri, Anna Galli, Luca Arcaini
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Letter
Oncology
Marzia Varettoni, Silvia Mangiacavalli, Sara Rattotti, Claudio Salvatore Cartia, Chiara Cavalloni, Franca Rossetti, Virginia Valeria Ferretti, Fabio Bergamini, Chiara Trotti, Nicolas Fiorelli, Giuseppina Pagani, Caterina Zerbi, Jacqueline Ferrari, Caterina Cristinelli, Alba Muzzi, Carlo Marena, Fausto Baldanti, Raffaele Bruno, Luca Arcaini
LEUKEMIA & LYMPHOMA
(2021)
Review
Oncology
Paolo Bernasconi, Oscar Borsani
Summary: In AML, detecting measurable residual disease (MRD) using sensitive techniques has become crucial, with MRD positivity indicating poor clinical outcomes and MRD eradication potential for improvement. Detection of MRD in non-M3 AML by consensus-based guidelines is the most relevant predictor of clinical outcome, with conversion from MRD positivity to negativity showing favorable outcomes. Strategies targeting driver mutations, apoptosis, methylation patterns, and leukemic proteins may help achieve MRD negativity in AML patients.
Article
Oncology
S. Ferrero, Massimo Gentile, Luca Laurenti, Francesca Romana Mauro, Maurizio Martelli, Paolo Sportoletti, Carlo Visco, Pier Luigi Zinzani, Alessandra Tedeschi, M. Varettoni
Summary: A panel of Italian experts convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases, particularly in patients with WM. This position paper represents the collective analysis, evaluation, and opinions of the panel, addressing frequently asked questions by clinicians based on currently available evidence.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Oncology
Pier Luigi Zinzani, Maurizio Martelli, S. Ferrero, Massimo Gentile, Luca Laurenti, Francesca Romana Mauro, Paolo Sportoletti, Alessandra Tedeschi, M. Varettoni, Carlo Visco
Summary: The introduction of BTK inhibitors has transformed the management of MCL patients, with ibrutinib being widely approved and many new inhibitors in development. Novel agents with potential clinical activity are also being studied in clinical trials. A group of experts convened a meeting to address outstanding issues and provide clinical guidance, resulting in an expert opinion statement with analysis, evaluation, and recommendations.
HEMATOLOGICAL ONCOLOGY
(2022)
Letter
Oncology
Marzia Varettoni, Silvia Zibellini, Michele Merli, Daniela Drandi, Cristina Jimenez, Daniela Furlan, Virginia Valeria Ferretti, Nicole Fabbri, Irene Dogliotti, Chiara Varraso, Martina Ferrante, Emilia Cappello, Veronica Peri, Chiara Cavalloni, Michela Borriero, Giulia Vittoria Facchetti, Simone Ferrero, Luca Arcaini, Ramon Garcia-Sanz
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Oncology
Pier Luigi Zinzani, Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, Giovanni Barosi
Summary: Zanubrutinib has been approved for the treatment of various lymphoproliferative disorders, providing a significant breakthrough for patients who are resistant or relapse after recommended therapies. Due to the lack of systematic studies and comparative randomized clinical trials, the optimal use of zanubrutinib in approved indications presents challenges, especially in earlier stages of the disorders. This article presents the results of expert panel discussions aimed at identifying unmet clinical needs and proposing recommendations for the management of these needs.
HEMATOLOGICAL ONCOLOGY
(2023)